AXIM Biotechnologies (OTC:AXIM) applied for a patent with the United States Patent and Trademark Office involving a chewing gum composition with controlled release of cannabinoids against opioid dependence.
As quoted in the press release:
“Opioid addiction is a serious global problem that affects the health, social, and economic welfare of all societies. Opioid addiction therapy depends on a variety of techniques. One of them is the replacement therapy, where an opioid is replaced with another less potent and less addictive opioid that curbs the craving and reduces withdrawal symptoms, while maintaining the person’s mental state such that the person is still able to function normally,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech.
In addition, by providing replacement opioids such as opioid agonists and/or antagonists and cannabinoids in a chewing gum form, users may avoid adverse effects caused by injection, smoking and other delivery methods. The act of chewing is also known to be neuroprotective, destressing, it induces the release of reward hormones such as dopamine and serotonin, and improves oral health.
“This is another milestone achievement for AXIM Biotech. We believe we are the first to file patent application on using chewing gum as the delivery system for opioids and combination of opioids and cannabinoids. With this filing, we are one stop closer toward entering the $100 billion market in pain management,” said Dr. Anastassov.